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Key points:  
 The composite of recurrent VTE and major bleeding was non-significantly lower for DOACs 
than LMWH. 
 DOACs should be used with caution in patients at high risk for bleeding. 
Abstract 
Direct oral anticoagulants (DOACs) are an emerging treatment option for cancer patients with acute 
venous thromboembolism (VTE), but studies have reported inconsistent results. This systematic 
review and meta-analysis compared the efficacy and safety of DOACs and low-molecular-weight 
heparins (LMWH) in these patients. MEDLINE, Embase, CENTRAL, and conference proceedings 
were searched to identify relevant randomized controlled trials. Additional data were obtained from the 
original authors to homogenize definitions for all study outcomes. The primary efficacy and safety 
outcomes were recurrent VTE and major bleeding, respectively. Other outcomes included the 
composite of recurrent VTE and major bleeding, clinically relevant non-major bleeding (CRNMB), and 
all-cause mortality. Summary relative risks (RR) were calculated in a random effects meta-analysis. In 
the primary analysis comprising 2,607 patients, the risk of recurrent VTE was non-significantly lower 
with DOACs than with LMWH (RR 0.68; 95% CI, 0.39 to 1.17). Conversely, the risks of major bleeding 
(RR 1.36; 95% CI, 0.55 to 3.35) and CRNMB (RR 1.63, 95%, 0.73 to 3.64) were non-significantly 
higher. The risk of the composite of recurrent VTE or major bleeding was non-significantly lower with 
DOACs than with LMWH (RR 0.86; 95% CI, 0.60 to 1.23). Mortality was comparable in both groups 
(RR 0.96; 95% CI, 0.68 to 1.36). Findings were consistent during the on-treatment period and in those 
with incidental VTE. In conclusion, DOACs are an effective treatment option for cancer patients with 






















Venous thromboembolism (VTE) is a common complication in patients with cancer. Its 
management in cancer patients is challenging because the risks of bleeding events and recurrent VTE 
during anticoagulant treatment are high.
1
 Until recently, subcutaneous low-molecular-weight heparin 
(LMWH) was the mainstay of treatment for cancer-associated VTE, because of the lower risk of 
recurrent VTE compared with vitamin K antagonists.
2,3
 However, LMWH is relatively expensive and 
the subcutaneous route of administration is often considered burdensome by patients, possibly 
leading to poor adherence.
4–6
 
Direct oral anticoagulants (DOACs) include apixaban, edoxaban, and rivaroxaban, which 
inhibit factor Xa, and dabigatran, which inhibits thrombin. These drugs are easy to use as they can be 
administered orally in fixed doses without routine monitoring. Based on their favorable safety profile 
compared to vitamin K antagonists, DOACs have been established as the recommended treatment for 
VTE in the general population.
7
  
Recently, several randomized controlled trials have compared DOACs with LMWH for 
treatment of VTE in patients with cancer associated VTE.
8–11
 Some of these trials showed that 
DOACs, compared to LMWH, were associated with a higher risk of bleeding,
8,9
 while others did 
not.
10,11
 These conflicting results could reflect differences in patient characteristics across the studies 
(i.e. index VTE and type and stage of cancer), heterogeneity in the definition of study outcomes, or 
variability in follow-up period analyses (i.e. complete follow-up period vs. on-treatment period). In 
addition, most studies were designed as non-inferiority studies and therefore had limited precision in 
evaluating the efficacy or safety of DOACs relative to LMWH. Hence, questions remain about the 
overall benefit-risk ratio of DOACs vs. LMWH for VTE treatment in cancer patients.  
In this systematic review and meta-analysis, we evaluated the efficacy and safety of DOACs 
versus LMWH for treatment of VTE in cancer patients. In addition, by collecting additional outcome 
data for the individual studies, this report extends current knowledge by 1) aggregating all current 
evidence using a uniform study outcome definition, 2) reporting a summary on-treatment analysis, 3) 
providing a subgroup analysis of patients with incidental VTE, and 4) performing an analysis of net 



















This study was registered (Open Science Framework (OSF): https://osf.io/vn9aq). The study report 
was prepared in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-




Search strategy and data collection  
A systematic literature search was performed on March 29
th
, 2020 in MEDLINE, Embase, and the 
Cochrane central register of controlled trials to identify randomized controlled trials that compared any 
DOAC with any low-molecular-weight heparin (LMWH) for the treatment of VTE in cancer patients by 
combining terms for VTE, deep vein thrombosis (DVT), pulmonary embolism (PE), cancer, and 
DOACs. No restrictions for year of publication or language were applied. The search strategy is shown 
in Supplementary Table 2. Additionally, a manual search was performed to identify relevant abstracts 
presented at the most recent conferences of the American Society of Hematology, the International 
Society on Thrombosis and Haemostasis (ISTH), European Society of Cardiology, and American 
College of Cardiology. All included studies were approved by their local Institutional Review Board 
Two reviewers (F.I.M and F.T.M.B.) independently screened titles, abstracts, and subsequently full 
texts for potentially eligible articles. Both reviewers independently assessed risk of bias using the 
Cochrane tool of bias assessment in randomized controlled trials version 2.0.
13
 Bias was assessed in 
the domains of randomization process, deviations from intended intervention, missing outcome data, 
measurement of outcome, and selection of the reported results. Data on study characteristics and 
outcomes were extracted using a standardized form. Discrepancies were resolved by consensus or 
contact with a third author (N.v.E).  
 
Inclusion criteria and outcomes 
Randomized controlled trials that compared a therapeutic dose of a DOAC with a therapeutic dose of 
LMWH (either full-dose or full-dose followed by reduced dose) in patients with acute symptomatic or 
incidental VTE and active cancer or a recent history of cancer were eligible. Active cancer was defined 
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study inclusion, ii) required cancer treatment in the 6 months before randomization, iii) was recurrent 
or metastatic, or iv) was a hematologic malignancy not in complete remission. A recent history of 
cancer was defined as a cancer diagnosis in the 2 years prior to inclusion and not fulfilling the criteria 
for active cancer. Any objectively confirmed symptomatic or incidental VTE was allowed as an index 
venous thromboembolic event, except superficial vein thrombosis.  
The primary efficacy outcome was recurrent VTE, defined as symptomatic or incidental new 
DVT of the upper or lower extremities, symptomatic or incidental PE involving segmental or more 
proximal pulmonary arteries, or fatal PE including unexplained death for which PE could not be ruled 
out. Splanchnic vein thrombosis, cerebral vein thrombosis, and arterial thromboembolic events were 
not part of the primary efficacy outcome.  
The primary safety outcome was major bleeding, defined using the ISTH criteria as overt 
bleeding associated with a drop in hemoglobin of 2 g per deciliter or more or transfusion of 2 or more 
units of blood, or that occurred in a critical site or contributed to death.
14
 Other safety outcomes were 
all-cause mortality, fatal recurrent VTE, fatal major bleeding, and clinically relevant non-major 
bleeding, which was defined using the ISTH criteria as overt bleeding not meeting the criteria for major 
bleeding but associated with the need for medical intervention, contact with a physician, interruption of 
the assigned treatment, discomfort, or impairment of activities of daily living.
14
 The definitions of fatal 
PE and major bleeding used in the original studies were accepted. The composite outcome of first 
recurrent VTE or major bleeding was also evaluated as a measure of net clinical benefit. 
We intended to evaluate all outcomes during a maximum of 6 months of follow-up in the 
intention-to-treat or modified intention-to-treat population which included all patients who were 
randomized and received at least one dose of the assigned study drug. Recurrent VTE and major 
bleeding events were also evaluated during the on-treatment period (while taking the assigned study 
drug or up to 3 days after discontinuation) in the per-protocol population as defined in the individual 
studies. If the per-protocol population was not specified, the (modified) intention-to-treat population 
was used for the on-treatment analysis. The certainty of evidence was graded according to the 
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The primary effect measure was the relative risk for DOACs compared with LMWH for all 
study outcomes. The secondary effect measure was the absolute risk reduction for DOACs relative to 
LMWH. Since relative risks are generally more consistent across studies than absolute risks,
15
 the 
anticipated absolute risk reduction was calculated by applying the summary estimate of the relative 
risk to the observed baseline risk in the LMWH groups, as is generally recommended.
15,16
  
Logit transformation and inverse variance weighting was used to calculate summary estimates 
using a Knapp-Hartung random-effects model, which is generally preferred in a meta-analysis of few 
studies.
17,18
 Forest plots were constructed for all back-transformed outcome measures with 
corresponding 95% confidence intervals. Between-study heterogeneity was assessed by calculating 
tau-squared (τ
2
) and I-squared (I
2
) using restricted maximum likelihood estimations.  
The primary analysis was restricted to studies that included patients with acute, symptomatic 
or incidentally detected lower-extremity DVT involving the popliteal, femoral, or iliac veins or the 
inferior vena cava, acute symptomatic PE, incidentally detected PE involving segmental or more 
proximal pulmonary arteries as the index event. A secondary analysis included results from studies 
that had enrolled patients with any type of VTE index event.  
A subgroup analysis was performed for patients whose index event was incidental VTE, which 
was defined as VTE events detected on radiologic imaging scans performed for reasons other than 
suspected VTE. Of the incidental VTE in the Hokusai VTE Cancer Study, only those confirmed by 
blinded adjudication were included.
19
  
Publication bias was explored by visual inspection of the funnel plots. No formal tests for 
publication bias were performed, because they lack statistical power when few studies are included. 
Since there were differences across studies in outcome definitions, reporting of on-treatment analyses, 
reporting of the composite outcome, and reporting of the subgroups gastrointestinal cancer and 
incidental index VTE, additional data were requested from the corresponding authors. 
Analyses were performed with R computing software, version 3.6.1 (R Foundation for 
Statistical Computing, Vienna, Austria, www.r-project.org), using the meta package version 4.9-2. 
 
Data sharing statement 


















The electronic database and manual searches for conference abstracts yielded 545 unique articles 
and one abstract, of which 215 were duplicates and 318 were excluded after screening of title and 
abstract. After full-text assessment, another nine studies were excluded because the study was either 
a duplicate (n=3), not a randomized trial (n=2), included a different population (n=3), or did not 
evaluate a DOAC (n=1) (Supplementary Figure 1). Inter-observer agreement for study selection was 
97% (Cohen’s kappa 0.72).  
Four randomized controlled trials were included in the meta-analysis, which had enrolled a 
total of 2,894 cancer patients with acute VTE.
8–11
 Study characteristics are specified in Table 1. In all 
studies, the proportion of patients with active cancer was 97% or higher. The included studies 
evaluated either apixaban 5 mg twice daily (ADAM-VTE and Caravaggio),
10,11
 edoxaban 60 mg once 
daily (Hokusai VTE Cancer),
8
 or rivaroxaban 20 mg once daily (SELECT-D).
9
 The patients in the 
control groups in all studies received subcutaneous dalteparin (200 IU per kilogram for the first 30 
days, followed by 150 IU per kilogram thereafter). One study included upper extremity and splanchnic 
DVT as index events,
10
 while the others limited inclusion to patients with proximal DVT or PE. All 
studies allowed inclusion of patients with incidental VTE. Two studies followed patients for 6 
months
10,11
 and two for 12 months.
8,9
 
Additional unpublished data were obtained for three studies to homogenize definitions and 
results,
8–10
 including the study outcome recurrent VTE without splanchnic or cerebral vein 
thrombosis,
9,10
 major gastrointestinal bleeding,
8
 outcomes for patients with incidental VTE,
9
 bleeding 
events during the on-treatment period according to our definition of a bleeding up until 3 days after 
study drug discontinuation,
8–10
 bleeding events in the overall study period,
10
 and the net clinical benefit 




Risk of Bias assessment 
Using the Cochrane tool of bias assessment in randomized controlled trials version 2.0, none of the 
studies was judged to be at high risk of bias for one of the bias domains. Despite the open-label study 
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outcome’ because outcomes were centrally adjudicated by committees blinded to treatment allocation. 
One study was assessed as having ‘some concerns’ in the bias domain of missing data, because 5%  
of patients were lost to follow-up.
10
 The results of the risk of bias assessment are presented in Figure 
1. Visual inspection of the funnel plot did not indicate evidence of publication bias (Supplementary 
Figure 2).  
 
Primary analysis 
In the three studies that restricted enrollment to patients with proximal DVT or PE (N=2,607),
8,9,11
 the 
risk of recurrent VTE was non-significantly lower in the DOAC group than in the LMWH group (RR 
0.68; 95% CI, 0.39 to 1.17; I
2
 0%; moderate quality evidence). With a baseline risk of recurrent VTE of 
8.3% in LMWH users, the absolute risk reduction with DOACs was -2.7% (95% CI, -5.1 to 1.4). 
Conversely, the risk of major bleeding was non-significantly higher in the DOAC group than in the 
LMWH group during the follow-up period (RR 1.36; 95% CI, 0.55 to 3.35; I
2 
15%; moderate quality 
evidence). With a baseline risk of major bleeding of 3.5% in LMWH users, the absolute risk increase 
with DOACs was 1.3% (95% CI, -1.6 to 8.3). Net clinical benefit – composite of first recurrent VTE or 
major bleeding was non-significantly lower in the DOAC than in the LMWH group (RR 0.86; 95% CI, 
0.60 to 1.23; I
2
 0%; moderate quality evidence), with an absolute risk reduction with DOACs of -1.6% 
(95% CI,-4.4 to 2.6). The risk of clinically relevant non-major bleeding was also non-significantly higher 
in the DOAC group than in the LMWH group (RR 1.63, 95% CI, 0.73 to 3.64; I
2 
49%; moderate quality 
evidence). Based on a baseline risk of clinically relevant non-major bleeding of 6.5% in LMWH users, 
the absolute risk increase with DOAC was 4.1% (95% CI, -1.8 to 17.2). All-cause mortality was 
comparable in both treatment groups (RR 0.96; 95% CI, 0.68 to 1.36; I
2 
30%; moderate quality of 
evidence). Figure 2 shows the forest plots of the relative risk of these study outcomes in both 
treatment groups. The risk of fatal VTE was non-significantly higher in the DOAC group than in the 
LMWH group (RR 1.25; 95% CI, 0.26 to 5.94; Supplementary Figure 3). Conversely, the risk of fatal 
bleeding was non-significantly lower in the DOAC group than in the LMWH group (RR 0.37; 95% CI, 
0.03 to 3.91; Supplementary Figure 3). The summary of findings, including absolute risk reduction and 
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During the on-treatment period, the risk of recurrent VTE was significantly lower in the DOAC 
group compared to the LMWH group (RR 0.60; 95% CI, 0.38 to 0.95; I
2
 0%; high quality evidence). 
The risk of major bleeding and clinically relevant non-major bleeding was not materially different than 
in the total observation period. Relative risks of recurrent VTE, major bleeding, and clinically relevant 
non-major bleeding during the on-treatment period are shown in Table 2 and Supplementary Figure 4. 
 
Subgroup with incidental VTE 
The primary analysis in patients with incidental VTE as their index event was based on data from 774 
cancer patients enrolled in three trials.
8,9,11
 Among patients with incidental VTE, the risk of recurrent 
VTE was non-significantly lower in the DOAC group than in the LMWH group (RR 0.54; 95% CI, 0.26 
to 1.11; I
2 
0%; moderate quality evidence). With a baseline risk of recurrence in the LMWH group of 
6.4%, the absolute risk reduction with a DOAC was -2.9 (95% CI, -4.7 to 0.7). The risk of major 
bleeding was non-significantly higher in patients with incidental VTE receiving DOACs than in those 
given LMWH (relative risk 1.29%; 95% CI, 0.74 to 2.28; I
2 
0%; moderate quality evidence). With a 
baseline risk of major bleeding in the LMWH group of 4.6%, the absolute risk increase with DOACs 
was 1.3 (95% CI, -1.2 to 5.9). There was no evidence of interaction between type of index VTE 
(symptomatic vs incidental VTE) and treatment for the study outcomes recurrent VTE (P=0.1677) or 
major bleeding (p=0.5225). The summary of findings for this subgroup in the primary analysis is shown 
in Table 3, and the corresponding forest plot of the relative risk in Supplementary Figure 5.  
 
Secondary analysis 
The secondary analysis, was based on data from 2,894 cancer patients with any acute VTE index 
event, from four trials.
8–11
 Overall, results were comparable to that of the primary analysis. The risk of 
recurrent VTE was non-significantly lower in the DOAC groups (RR 0.66; 95% CI, 0.39 to 1.13; I
2 
26%; 
moderate quality of evidence), while the risks of major bleeding (RR 1.32 95% CI, 0.70 to 2.47; I
2 
1%; 
moderate quality of evidence) and clinically relevant non-major bleeding (RR 1.60; 95% CI, 0.99 to 
2.60; I
2 
29%; moderate quality of evidence) were non-significantly higher. The risk of the composite of 
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group (RR 0.84; 95% CI, 0.63 to 1.34; I
2
 38%; moderate quality of evidence). All-cause mortality risk 
was similar in both groups (RR 0.99; 95% CI, 0.74 to 1.32; I
2 
37%; moderate quality of evidence) 
(Supplementary Figure 6; Supplementary Table 3). No fatal events were reported in the ADAM-VTE 
trial.   
In the on-treatment period, the risk of recurrent VTE was significantly lower in the DOAC group 
(RR 0.59; 95% CI, 0.35 to 0.99; I
2
 5%, high quality evidence), while the risk of major bleeding was 




quality evidence). The risk of 
clinically relevant non-major bleeding in this period was significantly higher in DOAC recipients (RR 
1.83, 95% CI, 1.06 to 3.14; I
2
 18%; high quality evidence) (Supplementary Figure 7; Supplementary 
Table 3). The ADAM-VTE trial did not report incidental index events, therefore this subgroup could not 
be evaluated in the secondary analysis.  
 
Discussion 
In this systematic review and meta-analysis, data from four randomized controlled trials that compared 
DOACs with LMWH for cancer-associated VTE were aggregated. The main finding is that, compared 
with LMWH, DOACs were associated with a 32% lower risk of recurrent VTE and a 36% higher risk of 
major bleeding, although both these effects were not statistically significant. The net clinical benefit, 
defined as the composite of recurrent VTE and major bleeding, was non-significantly lower in the 
DOAC group. Results did not change materially when only considering events during treatment with 
the study drug. 
 The results of this meta-analysis support DOACs as an acceptable treatment option for cancer 
associated VTE, thereby strengthening current guidelines.
20–22
 Results in patients with incidentally 
detected VTE, a group that is rapidly expanding because of the widespread use of high-resolution CT-
scanning for staging and follow-up of cancer patients, were consistent with those in patients with 
symptomatic events.  
Compared with LMWH, the reported risk of major bleeding and clinically relevant-non major 
bleeding was non-significantly higher with DOACs than with LMWH, suggesting that DOACs should be 
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cancer, as the majority of major bleeding events occurred in the gastrointestinal tract, in 36 of 62 
events (58%). An increased risk of major bleeding in patients with gastrointestinal cancer was 
observed in the Hokusai VTE Cancer and SELECT-D studies,
9,23,24
 but not in the ADAM-VTE study.
10
 
Despite these observations, the incidence of major bleeding in this patient group was not reported in 
the later Caravaggio study.
11
 However, the overall major bleeding risk was not increased in the 
apixaban recipients despite that one third (33%) of patients had gastrointestinal cancer. It is unclear 
whether these conflicting results between studies relate to the pharmacodynamics of the particular 
DOAC (apixaban vs. others). Although head-to-head comparisons between DOACs in the setting of 
atrial fibrillation or VTE are lacking, observational studies suggest that some DOACs may be 
associated with a lower risk of gastrointestinal bleeding than others.
25–27
 Another potential explanation 
could be the enrolment of fewer gastrointestinal cancer patients at high risk for bleeding in Caravaggio 
and ADAM-VTE studies, which were conducted after publication of the Hokusai VTE Cancer and 
SELECT-D study results. 
Overall, there were only few fatal VTE and major bleeding events in the studies (range, 0 to 
0.6%) resulting in relatively wide confidence intervals around the summary estimates. The risk of fatal 
VTE in each study may have been underestimated as adjudication of fatal VTE is often difficult in the 
cancer population when detailed information on death is not available.
28
 Case fatality rates for VTE 
were 6.8% in the DOAC group and 3.4% in the LMWH group, while case fatality rates for major 
bleeding were 1.6% and 10.4% in these groups, respectively. The apparent higher case fatality rate 
with LMWH could reflect a more severe course of bleeding than with DOACs, which was reported 
previously.
24
   
The majority of patients in the trials received systemic cancer therapy. Plasma concentrations 
of DOACs can be altered by drugs that inhibit or induce P-glycoprotein or cytochrome P450 3A4, 
including several chemotherapeutic agents, tyrosine kinase inhibitors, tamoxifen, and immune-
modulating agents such as dexamethasone.
29
 Unfortunately, we were not able to evaluate such 
potential interactions as data on this subgroup of patients was not available. More research is needed 
to better understand the pharmacokinetics of DOACs when given concurrently with cancer drugs.  
All trials in this meta-analysis had included a broad spectrum of cancer patients and the 
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65%. Nonetheless, important differences between the four individual trials included in this meta-
analysis should be noted. The risk of major bleeding in the Hokusai VTE Cancer, SELECT-D, and 
Caravaggio study ranged from 4% to 6% in the DOAC group, and from 3% to 4% in the LMWH group. 
In ADAM-VTE, which was not included in the primary analysis, there were no bleeding events in the 
DOAC group and only 2 in the LMWH group (1.4%). Possible explanations include differences in case-
mix as reflected by the substantially lower mortality risk in ADAM-VTE or because patients with upper-
extremity DVT and splanchnic vein thrombosis were enrolled in ADAM-VTE but not in the other 
studies. The secondary analysis, however, which included the ADAM-VTE study, did not yield 
materially different results.  
Strengths of this systematic review and meta-analysis include the availability of additional data from 
three studies, which allowed us to homogenize study outcomes, evaluate additional outcomes, and 
perform subgroup analyses for patients with incidental VTE. Between-study heterogeneity in the 
analyses was generally low and most of the included studies were considered to be at low risk of bias 
in all the bias domains. The study population comprised 2,894 cancer patients, of which the majority 
received cancer treatment and had metastatic disease, making the study groups representative of 
clinical practice. Since only four studies were included in this study, we used the Knapp-Hartung 
method to combine results, which less likely leads to artificially small confidence intervals.
17
 Therefore, 
our estimates of uncertainty, as reflected by the confidence intervals, may be more conservative than 
with other methods. However, the more commonly used DerSominian-Laird method for random effects 




Several limitations need to be acknowledged. Lack of detailed descriptions of patient 
characteristics precluded evaluation of several other important subgroups of patients, such as those 
with gastrointestinal cancer, urogenital cancer or hematological cancer. Precision in the individual 
trials and in this systematic review was limited for evaluating effects in the subgroup of patients with 
incidental VTE. Therefore, findings in this subgroup need to be interpreted with caution. All included 
studies were performed with an open-label design, since subcutaneous placebo injections were 
considered inappropriate. The risk of bias in outcome assessment was considered low because there 
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 The present findings show that DOACs are an effective treatment option, and safe for most 
cancer patients with acute VTE. DOACs should be used with caution in patients at high risk for 
bleeding. Choosing the optimal anticoagulant drug for cancer-associated VTE should be based on a 
careful balance of the risks of recurrent VTE and bleeding, the consideration of potential drug-drug 
interactions, and patient preference.  
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Figure 1. Risk of bias asssement. 
 
Figure 2. Forest plots of summary relative risks between direct oral anticoagulants and low-molecular-
weight heparin groups. 
Figure 2 legend: Results are based on the primary analysis, which included three studies that used pulmonary 
embolism or proximal deep-vein thrombosis as index event. For Caravaggio, bleeding events during the on-
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Table 1. Baseline characteristics and 6-month study outcomes of included randomized trials. 














































277 (53.1) 64±11 328 (62.8) 167 (32.0) 49 (9.4) 274 (52.5) 165 (31.6) 34 (6.5) 29 (5.6) 64 (12.3) 140 (26.8) 
Dalteparin N=524 263 (50.2) 63±12 329 (62.8) 173 (33.0) 63 (12.0) 280 (53.4) 140 (26.7) 46 (8.8) 17 (3.2) 43 (8.2) 127 (24.2) 
Select-D 2018 
Rivaroxaban N=203 116 (57.1) 67 (22-87) 150 (73.9) 108 (53.2) NR 118 (58.1) 94 (46.3) 7 (3.4) 11 (5.4) 25 (12.3) 48 (23.6) 




Apixaban N=150 72 (48.0) 64±11 81 (54.0) NR 8 (5.3) 
96 (64.0)  
 
48 (32.0) 0 (0) 0 (0) 9 (6.2) 23 (15.9) 
Dalteparin N=150 73 (48.7) 64±11 75 (50.0) NR 12 (8.0) 
97 (64.7)  
 
57 (38.0) 5 (3.5) 2 (1.4) 7 (4.9) 15 (10.6) 
Caravaggio 2020 
Apixaban N=576 292 (50.7) 67±11 304 (52.8) 116 (20.1) 45 (7.8) 
389 (67.5) 
¶ 
188 (32.6) 32 (5.6) 22 (3.8) 52 (9.0) 135 (23.4) 
Dalteparin N=579 276 (47.7) 67±11 334 (57.7) 114 (19.7) 61 (10.5) 
396 (68.4) 
¶ 
187 (32.3) 46 (7.9) 23 (4.0) 35 (6.0) 153 (26.4) 
* Number of patients in (modified) intention to treat analysis.  
†
 excluding splanchnic vein thrombosis and cerebral thrombosis. 


















 In the ADAM-VTE trial, baseline characteristics were presented for all 300 randomized patients, the analysis was performed in the mITT population (n=145 in the rivaroxaban 
group, n=142 in the dalteparin group) 
¶ Also included patients with recurrent locally advanced cancer. 
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Anticipated absolute effects 
Risk with 
DOACs 
Absolute risk difference 
Recurrent VTE  2607 (3 RCTs)  
⨁⨁⨁◯ 
MODERATE due to imprecision
a
 
0.68 (0.39 to 1.17)  8.3% 5.6% -2.7% (-5.1 to 1.4%) 
Major bleeding 2607 (3 RCTs) 
⨁⨁⨁◯ 
MODERATE due to imprecision
a
 
1.36 (0.55 to 3.35) 3.5% 4.8% 1.3% (-1.6 to 8.3%) 
Composite outcome of first recurrent 
VTE and major bleeding  
2607 (3 RCTs) 
⨁⨁⨁◯ 
MODERATE due to imprecision
a
 
0.86 (0.60 to 1.23)  11.1% 9.5% -1.6% (-4.4 to 2.6%) 
Clinically relevant non-major bleeding  2607 (3 RCTs) 
⨁⨁⨁◯ 
MODERATE due to imprecision
a
 
1.63 (0.73 to 3.64)  6.5% 10.6% 4.1% (-1.8 to 17.2%) 
All-cause mortality  2607 (3 RCTs) 
⨁⨁⨁◯ 
MODERATE due to imprecision
a
 
0.96 (0.68 to 1.36)  25.7% 24.7% -1.0% (-8.2 to 9.3%) 
On-treatment analyses: 
Recurrent VTE (on-treatment) 2440 (3 RCTs)  
⨁⨁⨁⨁ 
HIGH 
0.60 (0.38 to 0.95)  8.1% 4.9% -3.2% (-5.0 to -0.4%) 
Major bleeding 
(on-treatment) 
2440 (3 RCTs)  
⨁⨁⨁◯ 
MODERATE due to imprecision
a
 
1.43 (0.46 to 4.45) 3.2% 4.6% 1.4%(-1.7 to 11.0%) 
Clinically relevant non-major bleedin 
(on-treatment) 
2440 (3 RCTs)  
⨁⨁⨁◯ 
MODERATE due to imprecision
a
 



























Anticipated absolute effects 
Risk with 
DOACs 
Absolute risk difference 
*The risk in the DOAC group (and its 95% confidence interval) is based on the observed risk in the LMWH group and the relative effect of the intervention (and its 95% CI).  
a
 Graded down for imprecision due to a broad 95% CI intervals with a possible positive and negative effect of DOAC vs. LMWH.  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
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Anticipated absolute effects 
Risk with DOACs Absolute risk difference 
Recurrent VTE  774 (3 RCTs)  
⨁⨁⨁◯ 
MODERATE due to imprecision
a
 
0.54 (0.26 to 1.11)  6.4% 3.5% -2.9% (-4.7 to 0.7%) 
Major bleeding  774 (3 RCTs)  
⨁⨁⨁◯ 
MODERATE due to imprecision
a
 
1.29 (0.74 to 2.28)  4.6% 5.9% 
 
1.3% (-1.2 to 5.9%) 
*The risk in the DOAC group (and its 95% confidence interval) is based on the observed risk in the LMWH group and the relative effect of the intervention (and its 95% CI).  
a
 Graded down for imprecision due to a broad 95% CI intervals with a possible positive and negative effect of DOAC vs. LMWH.  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is 
substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
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Hokusai VTE Cancer Edoxaban Dalteparin VTE Low risk
SELECT-D Rivaroxaban Dalteparin VTE Some concerns
ADAM VTE Apixaban Dalteparin VTE High risk
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